Literature DB >> 7725741

Significance of P53 in human thyroid tumors.

D Simon1, P E Goretzki, V Gorelev, B Ebling, E Reishaus, J Lyons, H Haubruck, H D Röher.   

Abstract

Mutational changes in the p53 tumor suppressor gene are the most frequent genetic alterations in human malignant tumors. Studies have shown a correlation of p53 expression in breast cancer with tumor prognosis. In contrast to mutational activation of ras and GSP in thyroid tumors, little is known about the role of p53 in thyroid tumor development. Therefore thyroid tumors and thyroid tumor cell lines were studied for the presence of p53 mutations. Snap-frozen tissues from 57 differentiated thyroid carcinomas (DTCs) and 5 goiters were studied by immunohistochemical methods. A panel of six antibodies (pAb 240, 421, 1620, 1801, DO7, and CM1) was employed by using the ABC technique. Five cell lines from DTCs (FTC133, 236, 238, PTC337, MTC164) were examined by the same technique. Additionally, genomic DNA from the cells was amplified by the polymerase chain reaction (PCR) and the PCR product studied for p53 mutations (R273H) by mutation-specific oligonucleotide hybridization (MOH) and temperature gradient gel electrophoresis (TGGE) for the p53 exon 8. None of the benign thyroid tumors and 7 of 57 (12%) DTCs strongly express p53 with a heterogeneous distribution in the tumor tissue. All seven patients have metastatic disease or dedifferentiated tumors G3 (three of seven). CM1 was positive in two cell lines (FTC-133, PTC-337), questionable in FTC-238, and negative in FTC-236 and MTC-164. All three follicular cell lines, however, and the original tumor tissue showed the same p53 mutation (R273H) in MOH analysis and TGGE. P53 mutations are rare in thyroid tumors, but the presence of p53 mutations indicates a poor prognosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7725741     DOI: 10.1007/bf00353758

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  35 in total

1.  p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells.

Authors:  T Matozaki; C Sakamoto; T Suzuki; K Matsuda; T Uchida; O Nakano; K Wada; H Nishisaki; Y Konda; M Nagao
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

Review 2.  Biochemical properties of the growth suppressor/oncoprotein p53.

Authors:  M Montenarh
Journal:  Oncogene       Date:  1992-09       Impact factor: 9.867

3.  The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.

Authors:  M Scheffner; K Münger; J C Byrne; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

4.  Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; A Rejthar; J Kovarík; D P Lane
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

5.  Expression of p53 protein in infiltrating and in-situ breast carcinomas.

Authors:  R A Walker; S J Dearing; D P Lane; J M Varley
Journal:  J Pathol       Date:  1991-11       Impact factor: 7.996

Review 6.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

7.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.

Authors:  J Isola; T Visakorpi; K Holli; O P Kallioniemi
Journal:  J Natl Cancer Inst       Date:  1992-07-15       Impact factor: 13.506

8.  Functional interaction of p53 with HPV18 E6, c-myc and H-ras in 3T3 cells.

Authors:  T M Chen; V Defendi
Journal:  Oncogene       Date:  1992-08       Impact factor: 9.867

9.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  2 in total

Review 1.  Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects.

Authors:  N J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  Development and characterization of six new human papillary thyroid carcinoma cell lines.

Authors:  Ying C Henderson; Soon-Hyun Ahn; Junsun Ryu; Yunyun Chen; Michelle D Williams; Adel K El-Naggar; Mihai Gagea; Rebecca E Schweppe; Bryan R Haugen; Stephen Y Lai; Gary L Clayman
Journal:  J Clin Endocrinol Metab       Date:  2014-11-26       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.